TB Alliance Launches Upskill TB Platform in Collaboration with Indonesia’s Ministry of Health and RPRI Foundation
Digital Training Platform, Upskill TB, Strengthens Capacity to Deliver New DR-TB Treatments JAKARTA (October 9,…
DR-TB Regimen Will Save 190,000+ Additional Lives and $1.29B by 2035
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing…
New Study Finds Investing in Shorter, More Effective TB Treatment Pays Off
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms…
TB Alliance Welcomes WHO Prequalification of Lupin’s Pretomanid Product
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been…
Desmond Tutu TB Centre at Stellenbosch University: Championing Children in the Fight Against TB
In the global fight to end tuberculosis (TB), the Desmond Tutu TB Centre (DTTC) at…
TB Alliance Appoints Dr. Soraya Madani as Senior Vice President, Program and Alliance Management
New York, NY (August 29, 2025) – TB Alliance announced the appointment of Dr. Soraya…
TB Alliance Congratulates Dr. Kathleen Schostack on Her Retirement
As Senior Vice President of Program and Alliance Management, Dr. Schostack played a vital role…
Bangladesh TB Leaders Build Momentum for Shorter, Safer Drug-Resistant Tuberculosis Treatment
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and…
New Study Affirms Financial and Public Health Advantages of Treating Drug-Resistant TB with BPaL-Based Regimens in India
A new economic evaluation has added powerful evidence to the already strong case for wide,…